Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori

References

• Jones PA, De Clerck YA. Extracellular matrix destruction by invasive tumor cells. Cancer Metastasis Rev 1982; 1: 289–317
   PubMedGoogle Scholar
• Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, De Carlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197–250
   PubMedGoogle Scholar
• Matrisan LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121–5
   PubMed Web of Science ®Google Scholar
• Dano K, Andreasen PA, Gronbahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139–66
   PubMed Web of Science ®Google Scholar
• Vassalli JD, Sappino A, Belin D. The plasmonigen activator/plasmin system. J Clin Invest 1991; 88: 1067–72
   PubMed Web of Science ®Google Scholar
• Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49: 117–37
   PubMedGoogle Scholar
• Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator, proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104: 801–4
   PubMed Web of Science ®Google Scholar
• Allan EH, Martin TJ. The plasminogen activator inhibitor system in bone cell function. Clin Orthop Relat Res 1995; 313: 54–63
   Google Scholar
• Takahashi K, Uwabe Y, Sawasaki Y, Kiguchi T, Nakamura H, Kashiwabara K, et al. Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells. Am J Physiol 1998; 275: 47–54
   Web of Science ®Google Scholar
• Iwamoto J, Takahashi K, Mizokami Y, Ohtsubo T, Miura S, Narasaka T, et al. Expression of urokinase-type plasminogen activator and its receptor in gastric fibroblasts and effects of nonsteroidal anti-inflammatory drugs and prostaglandin. Dig Dis Sci 2003; 48: 2247–56
   PubMed Web of Science ®Google Scholar
• Reilly D, Andreasen PA, Duffy MJ. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay. Blood Coagul Fibrinolysis 1991; 2: 47–50
   PubMed Web of Science ®Google Scholar
• Miseljic S, Galandiuk S, Myers SD, Wittliff JL. Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in colon disease. J Clin Lab Anal 1995; 9: 413–7
   PubMed Web of Science ®Google Scholar
• Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, et al. The prognostic impact of the urokinase-type plasminogen activator system is associated with tumor differentiated in gastric cancer. Eur J Surg Oncol 1996; 22: 74–7
   PubMed Web of Science ®Google Scholar
• Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 1997; 79: 878–83
   PubMed Web of Science ®Google Scholar
• De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator, u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 1998; 58: 2234–9
   PubMed Web of Science ®Google Scholar
• Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41: 4629–36
   PubMed Web of Science ®Google Scholar
• Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381–7
   PubMed Web of Science ®Google Scholar
• Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 1996; 77: 1079–88
   PubMed Web of Science ®Google Scholar
• Sier CFM, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven HJM, Lamers CBHW. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 1993; 34: 80–5
   PubMed Web of Science ®Google Scholar
• Nekarda H, Schmitt M, Kurt U, Wenninger A, Vogelsang H, Becker K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54: 2900–7
   PubMed Web of Science ®Google Scholar
• De Petro G, Tavian D, Copeta A, Portolani N, Giulini MS, Barlati S. Expression of urokinase-type plasminogen activator (uPA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 1998; 58: 2234–9
   PubMed Web of Science ®Google Scholar
• Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991; 51: 274–81
   PubMed Web of Science ®Google Scholar
• Wilhelm O, Schmitt M, Hõhl S, Senekowitsch R, Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995; 13: 296–302
   PubMed Web of Science ®Google Scholar
• Mori N, Sato H, Hayashibara T, Senba M, Geleziunas R, Wada A, et al. Helicobacter pylori induces matrix metalloproteinase-9 through activation of nuclear factor κB. Gasteroenterology 2003; 124: 983–92
   PubMed Web of Science ®Google Scholar
• Crawford HC, Krishna US, Israel DA, Matrisian LM, Washington MK, Peek RM, Jr. Helicobacter pylori strain-selective induction of matrix metalloproteinase-7 in vitro and within gastric mucosa. Gastroenterology 2003; 125: 1125–36
   PubMed Web of Science ®Google Scholar
• Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991; 324: 1043–8
   PubMed Web of Science ®Google Scholar
• Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89: S116–S28
   PubMed Web of Science ®Google Scholar
• Okusa Y, Ichikura T, Mochizuki H, Shinomiya N. Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines. Int J Oncology 2000; 17: 1001–5
   PubMed Web of Science ®Google Scholar
• Herszènyi L, Plebani M, Carrao P, De Paoli M, Cardin R, Di Mario F, et al. Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. Am J Gastroenteol 1997; 92: 843–7
   PubMed Web of Science ®Google Scholar
• Götz JM, Vergouwe Y, Verspaget HW, Biemond I, Sier CFM, Lamers CBHW, et al. Gastric mucosal plasminogen activators in Helicobacter pylori infection. Dig Dis Sci 1996; 41: 1577–82
   PubMed Web of Science ®Google Scholar
• Kitadai Y, Sasaki A, Ito M, Yanaka S, Oue N, Yasui W, et al. Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric cancer cells. Bio Chem Res Comm 2003; 311: 809–14
   PubMed Web of Science ®Google Scholar
• Montemurro P, Barbuti G, Dundon WG, Giudice GD, Rappuoli R, Colucci M, et al. Helicobacter pylori neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells. J Infect Dis 2001; 183: 1055–62
   PubMed Web of Science ®Google Scholar
• Watanabe O, Takahashi K, Kishi K, Nakamura H, Hashimoto T, Narushima K, et al. The effect of hypoxia on the expression of the urokinase-type plasminogen activator and plasminogen activator inhibitor-1 by human pulmonary fibroblasts. J Tokyo Med Univ 2001; 59: 447–54
   Google Scholar
• Shapiro RL, Duquette JG, Roses DF, Nunes I, Harris MN, Kamino H, et al. Induction of primary cutaneous malanocytic neoplasms in urokinase-type plasminogen activator-deficient and wildtype mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996; 56: 3597–604
   PubMed Web of Science ®Google Scholar
• Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is related in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60: 5839–47
   PubMed Web of Science ®Google Scholar
• Rabbani SA, Mazar AP. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 2001; 10: 393–416
   PubMedGoogle Scholar
• Phadnis SH, Ilver D, Janzon L, Normark S, Westblom TU. Pathological significance and molecular characterization of the vacuolating toxin gene of Helicobacter pylori. Infect Immun 1994; 62: 1557–65
   PubMed Web of Science ®Google Scholar
• Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993; 90: 5791–95
   PubMed Web of Science ®Google Scholar
• Crabtree JE, Farmery SM, Lindley IJD, Figura N, Peichl P, Tompkins DS. CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines. J Clin Pathol 1994; 47: 945–50
   PubMed Web of Science ®Google Scholar
• Crabtree JE. Immune and inflammatory responses to Helicobacter pylori infection. Scand J Gastroenterol 1996; 31(Suppl 215)3–10
   Web of Science ®Google Scholar
• Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovski M, et al. Cag, a pathogenicity island of Helicobacter pylori, encodes type-l specific and disease-associated virulence factors. Proc Natl Acad Sci USA 1996; 93: 14648–53
   PubMed Web of Science ®Google Scholar
• Li SD, Kersulyte D, Lindley IJD, Neelam B, Berg DE, Crabtree JE. Multiple genes in the left half of the cag pathogenicity island of Helicobacter pylori are required for tyrosine kinase-dependent transcription of interleukin-8 in gastric epithelial cells. Infect Immun 1999; 67: 3893–9
   PubMed Web of Science ®Google Scholar
• Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58: 227–9
   PubMed Web of Science ®Google Scholar
• Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell 1995; 80: 529–32
   PubMed Web of Science ®Google Scholar
• Aihara M, Tsuchimoto D, Takizawa H, Azuma A, Wakabe H, Ohmoto Y, et al. Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45. Infect Immun 1997; 65: 3218–24
   PubMed Web of Science ®Google Scholar
• Keates S, Hitti YS, Upton M, Kelly CP. Helicobacter pylori infection activates NF-κB in gastric epithelial cells. Gastroenterology 1997; 113: 1099–109
   PubMed Web of Science ®Google Scholar